Interpreting the Data with Tirzepatide

In an interview with CMHC co-chair Dr. Anne Peters, Juan Frías, MD, shared his thoughts about the data with tirzepatide across key phase 3 trials, and the potential role of this agent in the management of patients with type 2 diabetes, as well as in the management of obesity (recorded October 21, 2022).

[@PinkOwl31]

10:19- the info about being on oral birth control while taking GLP-1s is very important. Thank you for mentioning this, i dont hear anyone else talking about this.

[@joanaileenwaggonnerc]

I have not seen anyone speak to the wonderful effect to digestion! I want to say that my digestion has improved, that I feel the adsorption of nutriments and no longer see lots of undigested food in my stools!

[@jooxumja]

Will compounded tirzepatide be taken off the market ? Is there a risk for that?

[@dab7963]

Thanks for a great video. I am just starting. Entering week 3 on 2.5 and my blood sugar went from 144 to 119 and I have lost 6.2 pounds. Once a patient reaches let's say 65 pounds weight loss and a great A1C then what. Research says once off the drug 2/3 of people regain the weight and I'm assuming also probably return to a higher A1C. Is this drug something that someone should be on long-term?

[@TheTriciaLife]

I was told it’s for a lifetime.

[@dab7963]

@@TheTriciaLife if it maintains the weight loss then it's worth it.

[@wendyheller3283]

It’s for the treatment of type2 diabetes, folks. Please get Wegovy for your obesity treatment & stop using up supplies of this medication!

[@Gary-bk7wrm]

It's lifetime, particularly for diabetics with diabetes 2.

[@jimmyp7657]

Oh my gosh! This is like being back in college: instructors trying to fill up the time to justify an one hour lecture! Let's just get to the bullet points...